Hsp90 inhibitors are a new class of emerging anticancer agents. Hsp90 is a critical molecular chaperone for the activation of many oncogenic proteins, including C-Raf.
INTRODUCTION
Sorafenib is a Raf kinase inhibitor that has proven clinical efficacy in advanced renal and hepatocellular cancer. It is currently approved by the Food and Drug Administration for use in those malignancies 1, 2 . B-Raf and C-Raf (wild-type and mutant) are involved in angiogenic development and are both inhibited by sorafenib 3 .
Activating mutations of B-Raf are found in about 70% of melanoma cell lines and in other common solid tumor cell lines, such as those of breast cancer and lung cancer 4 .
Heat shock protein 90 (Hsp90) is a chaperone protein integral to maintaining the proper configuration of important cellular signaling proteins 5 . Raf-1 kinase is one of the client proteins of Hsp 90 6 . Other important client proteins include Akt kinase, Bcr-Abl kinase, CDK4, HER2 and HIF-1alpha. 5 Inhibition of Hsp90 causes abnormal folding of its client proteins resulting in their degradation by the ubiquitin proteasome pathway. [5] [6] [7] 17-demethoxy-allylaminogeldanamycin/17-AAG (tanespimycin) is a benzoquinone ansamycin antibiotic with antiproliferative activity related to Hsp90 inhibition 8 
.
Tanespimycin acts by binding to the hydrophobic ATP/ADP-binding site of Hsp90. 9 Tumor Hsp90 is present in multi-chaperone complexes with high ATPase activity, and possesses 100-fold higher binding affinity for tanespimycin, which provides a potential tumor-selective effect. 9 In a stressful cellular environment, as may exist in tumors due to the continued production of proteins necessary to sustain proliferation, Hsp90 accumulates and has an essential role in maintaining oncogene function and activation. 10 The role of Hsp90 inhibition could also be important in augmenting the Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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effects of other anti-cancer therapies that induce tumor cell stress 11 . Previous in vitro studies exploiting Hsp90 inhibition in combination with Raf-kinase inhibition 12 reported cytotoxic synergy with regards to mitochondrial injury and apoptosis induction between tanespimycin and UCN-01, a protein kinase C, and a Raf-kinase inhibitor in leukemia cells. Decreased Akt-activation and marked downregulation of C-Raf, Mek-1 and 2, and MAP-kinases were noted with the combination therapy, compared to either agent alone.
Raf-1 kinase inhibition antagonizes the activation of the nuclear factor kappa B (NF-kB) transcription factor signaling pathway 13 and also abrogates the stimulation of NF-kB by tumor necrosis factor alpha and interleukin-1 beta, thereby affecting the progression and proliferation of tumor cells 13 .
The proposed rationale for evaluating tanespimycin and sorafenib in combination is that the raf-kinase inhibition resulting from sorafenib is likely to be increased with the modulation of Hsp90 and could result in enhanced degradation of certain Raf isoforms 14 .Tanespimycin can also affect a number of other Hsp90 client proteins that are critical to cellular function. Independent of Raf pathway modulation, sorafenib is known to inhibit VEGF-R kinase action directly, and 17-AAG has also demonstrated VEGF-related signaling blockade 15 . The combination of sorafenib and 17AAG could potentially act at both distinct and related pathways to affect cancer cell proliferation and angiogenesis.
Patients and Methods:
Research. 
Treatment Plan:
Therapy was started with a fixed oral sorafenib dose of 400 mg twice daily for the first 14 days (cycle 1). Sorafenib was administered with at least 250 mL of water without regard to meals but preferably with a low to moderate fat meal. Subsequently tanespimycin was started as an intravenous infusion, at escalating dose levels. starting at 300 mg/m, The linear calibration curve was constructed over the sorafenib concentration range of 5 to 2,000 ng/mL. The intra-and inter-day precision and accuracy were within 15% of deviations. tanespimycin plasma concentrations were determined using a validated high-performance liquid chromatography method, as reported previously. 18 PK parameters for sorafenib and tanespimycin in individual patients were estimated using noncompartmental analysis with the computer software program 
Pharmacodynamic (PD) Sample Collection and Processing
Blood samples were collected in two BD Vacutainer CPT™ tubes with sodium heparin before therapy, 7 days after beginning sorafenib and 72 hours after the first and third tanespimycin administrations (days 1 and 15 of cycle 2) . Stability studies have shown that such samples are stable for 24 hours at room temperature. The blood was centrifuged within 2 hours at room temperature and at 1800xg for 15 minutes following the manufacturer's instructions. The plasma layer was carefully removed without disturbing the peripheral blood mononuclear cells (PBMC). The PBMC of each patient were pooled and washed twice, first with ice-cold phosphate-buffered saline (PBS) followed by Bio-Plex™ (BioRad, Hercules, CA) cell wash buffer before being subjected to lysis using 75μl Bio-Plex™Cell Lysis buffer. Lysates were processed following the antibodies. Beta-actin was used as a loading control. A chemiluminescence-based developing system from Millipore was used with Kodak Biomax films that were scanned and analyzed. To account for differences in amounts of protein loaded and variability of assay conditions, the quantification of signal intensities was performed by relating the expression of a particular protein before and after treatment to the intensity of the actin band in the same specimen. Signals were quantified using NIH Image J software to measure the mean signal intensity (grey scale) value and its integrated density.
Resulting absolute intensities were determined, and a relative intensity value was obtained by dividing the absolute intensity of protein X by that of the beta-actin loading control. Whole cell lysates from the Hs578T breast cancer cell line, and the PC-3 prostate cancer cell line were used as positive controls. 
Statistical methods
The data from this Phase I trial were summarized using descriptive statistics, including point estimates and confidence interval (CI) estimates. The PD variables were presented using multiple box plots. Baseline (Day -14) levels of the PD variables were compared by clinical benefit (CB) status (yes/no) using the exact version of the Wilcoxon rank sum test (2-sided). CB was defined as either partial response (PR) or stable disease (SD). Among CB patients, the levels of PD variables at Day -1, Day +4, and Day +18 were compared vs baseline (Day -14) using the exact version of the Wilxocon signed-rank test. Since these analyses of the PD variables were hypothesis generating only, no adjustment for multiple comparisons was applied.
Sorafenib C max and AUC τ values (on day -1) and in combination with tanespimycin (on day 1) were compared using the paired t-test.
Time to progression (TTP) was measured from date of treatment start, until date of documented disease progression..If no progression occurred, patients were censored for TTP as of the date of their last tumor assessment. Overall survival (OS) was measured from date of treatment start, until date of death from any cause. Patients still alive were censored for OS as of the date of last follow-up for vital status determination.
The censored TTP and OS distributions were estimated with standard Kaplan-Meier (K-M) methods. Due to the modest sample size (or number of events), time-to-event (TTE) statistics (e.g., median, 6-month rate, ctc.) were estimated more conservatively using linear interpolation among successive event times on the K-M curves. 
Results

Patient Characteristics
Twenty-eight patients were consented, however one was deemed ineligible due to presence of brain metastases in pre-study screening. One patient died during the first cycle of therapy, considered to be possibly related to study medication. Three patients had to discontinue therapy after the first cycle due to severe toxicity from sorafenib alone. All twenty-seven patients were evaluable for the primary endpoint of toxicity assessment, but twenty three patients were response evaluable. Twelve patients with renal cancer were enrolled, of which 2 were untreated, 7 had received prior VEGF inhibitor therapy, 2 had received prior chemotherapy and 1 had received immunotherapy. None of the patients had received prior sorafenib therapy. Patient characteristics are summarized in Table 1 .
Treatment Administered and Dose Modifications
A total of 114 cycles of treatment were administered, with a median of 4 cycles 
limiting toxicity. If patients required a dose reduction of sorafenib during the first 14 days of therapy, then they were not started on tanespimycin. Hence all the dose reductions were in the patients who stayed on therapy beyond 2 cycles, as they were deriving clinical benefit.
Toxicity
Twenty-seven patients were evaluable for toxicity ( Table 2 The most prevalent toxicities related to the combination were nausea and emesis. One death, possibly attributed to study medication occurred.
Response and Survival
Twenty-three patients received at least 2 cycles and were evaluable for response. Of these, two (9%) demonstrated a partial remission (PR); one with thyroid cancer and one with renal cancer, and fourteen (61%) had stable disease (SD). Disease
Research. of 12.5 μM (39%) and 13.1 μM (46%), respectively, P = 0.437; it had the mean AUC τ of 90.7 μM*h (44%) and 85.0 μM*h (39%), respectively, P = 0.435 [ Table 3 ].
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Following intravenous infusion, C max (end of infusion) and AUC of tanespimycin and its major metabolite, 17-AG, increased with increasing tanespimycin dose ( Figure   2B ). On day 1, following the 3-hour intravenous infusions of 300, 350, 400, and 450 mg/m 2 , the mean tanespimycin C max were 6.0 μM (range 4.4 to 7.9 μM, n = 3), 10.9 μM (range 7.8 to 18.3 μM, n = 6), 10.3 μM (range 6.6 to 13.3 μM, n = 3), and 15.2 μM (range 11.9 to 18.6 μM, n = 2), respectively ( Figure 2B ). Tanespimycin C max and 17-AG C max were similar on days 1 and 15, suggesting that tanespimycin PK were not 
Pharmacodynamics
The markers below were evaluated, and their individual associations with clinical benefit were explored (Figure 3) . Clinical benefit was defined as either PR, MR or SD.
Biomarker levels are reported cumulatively for all dose levels because PK revealed that the minimum tanespimycin concentrations achieved in our patient samples were considerably higher (see Figure 2 and PK Results above) than the minimum concentrations reported to produce pharmacodynamic effects in prior studies conducted in xenograft models (123 nM to 20 mM) 19, 20 .
Other Correlates
Four of six patients had a decrease in c-Raf. Three of the four patients demonstrated clinical benefit ( Figure 3C ). Three patient samples showed a decline in pErk levels ( Figure 3D ]. An example of a remarkable post-therapy decline in c-Raf is Hand-foot syndrome and hepatotoxicity were the dose-limiting toxicities.
The sorafenib concentrations noted were consistent with previously published data 21 . The PK revealed a dose-dependent increase in tanespimycin and metabolite concentrations. The tanespimycin concentrations were similar to those reported in prior trials [22] [23] [24] .and tanespimycin did not significantly alter the systemic exposure of sorafenib and its N-oxide metabolite.
Tanespimycin modifies Hsp90 and Hsp70 levels in tumor cells in vitro and in vivo 19, 20, 25 . This led us to include Hsp90 and Hsp70 assessment as correlates in our trial design, to establish proof of principle of target inhibition. The PK data showed that tanespimycin was detected in the serum of all patients, independent of the administered dose and above the concentrations that we have previously defined necessary to modulate the target, and Hsp90 client proteins, in cell lines, and human xenograft tumor 
tanespimycin in animal models, and compared PD in tumor to PBMC samples. Their results showed, that changes in molecular biomarkers that occur in tumors, are well represented in PBMCs at drug concentrations required for therapeutic efficacy 23 . The latter suggests that the use of PBMCs to assess PD effects of tanespimycin is informative, even at the lowest concentrations achieved in our study. However, the association between Hsp90 decrease in PBMCs, and observed clinical efficacy is hypothesis-generating only and is limited by the small sample size and variations in dose and tumor type that are inherent in a phase I study. 
